BioLineRx to Report 2024 Annual Results on March 31, 2025

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, March 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. A replay of the call will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until April 2, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events.

CONTACTS:

United States     
Irina Koffler
LifeSci Advisors, LLC
ikoffler@lifesciadvisors.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2024-annual-results-on-march-31-2025-302409115.html

SOURCE BioLineRx Ltd.